ADARx Pharmaceuticals, Inc. ADRX
13.30 USD -0.27 (-1.99%)
At closeNov 11, 2026, 4:00 PM EST
13.30 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
13.17 Day range 14.07
13.23 52-week range 20.64
- YTD
- -31.27%
- 1 year
- -31.27%
News
globenewswire.com ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, today announced…
benzinga.com JP Morgan Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $38 JP Morgan analyst Tessa Romero initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $38.
benzinga.com This Restaurant Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts initiated bullish coverage on ADRX ($32), NWSA ($35), MOD ($275), SITM ($750) and QSR ($85), with Overweight, Outperform or Buy ratings.
benzinga.com UBS Initiates Coverage On Adarx Pharmaceuticals with Buy Rating, Announces Price Target of $35 UBS analyst Michael Yee initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Buy rating and announces Price Target of $35.
benzinga.com Morgan Stanley Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $32 Morgan Stanley analyst Michael Ulz initiates coverage on Adarx Pharmaceuticals (NASDAQ:ADRX) with a Overweight rating and announces Price Target of $32.
globenewswire.com ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering
gurufocus.com First Look: Disney Layoffs, Apple Smart Home Launch, Goldman CEO Talks Prefer to listen? Hear this as a ~5-minute audio briefing on The GuruFocus Brief.Stock NewsKen Griffin donates $3B to Carnegie Mellon: Citadel CEO Ken Griffin p
reuters.com ADARx Pharmaceuticals raises $446.3 million in upsized US IPO ADARx Pharmaceuticals said on Thursday it had raised $446.3 million in an upsized US initial public offering, reflecting growing investor appetite for biotech listings.
globenewswire.com ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the…